Logo image of ABP

ABPRO HOLDINGS INC (ABP) Stock Fundamental Analysis

NASDAQ:ABP - Nasdaq - US0008471031 - Common Stock - Currency: USD

0.3154  +0.05 (+18.53%)

After market: 0.318 +0 (+0.82%)

Fundamental Rating

0

ABP gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. Both the profitability and financial health of ABP have multiple concerns. ABP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ABP had negative earnings in the past year.
In the past year ABP has reported a negative cash flow from operations.
ABP Yearly Net Income VS EBIT VS OCF VS FCFABP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

ABP has a worse Return On Assets (-396.00%) than 94.78% of its industry peers.
Industry RankSector Rank
ROA -396%
ROE N/A
ROIC N/A
ROA(3y)-240.71%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABP Yearly ROA, ROE, ROICABP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABP Yearly Profit, Operating, Gross MarginsABP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

ABP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABP has more shares outstanding
Compared to 1 year ago, ABP has a worse debt to assets ratio.
ABP Yearly Shares OutstandingABP Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M 50M
ABP Yearly Total Debt VS Total AssetsABP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ABP has an Altman-Z score of -46.17. This is a bad value and indicates that ABP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -46.17, ABP is doing worse than 91.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -46.17
ROIC/WACCN/A
WACC9.14%
ABP Yearly LT Debt VS Equity VS FCFABP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ABP has a Current Ratio of 0.19. This is a bad value and indicates that ABP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.19, ABP is not doing good in the industry: 95.50% of the companies in the same industry are doing better.
A Quick Ratio of 0.19 indicates that ABP may have some problems paying its short term obligations.
ABP's Quick ratio of 0.19 is on the low side compared to the rest of the industry. ABP is outperformed by 95.32% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ABP Yearly Current Assets VS Current LiabilitesABP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

ABP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2966.01%.
The Revenue has grown by 289.36% in the past year. This is a very strong growth!
EPS 1Y (TTM)-2966.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-776.85%
Revenue 1Y (TTM)289.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

ABP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -23.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y-11.8%
EPS Next 3Y-23.31%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABP Yearly Revenue VS EstimatesABP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 50K 100K 150K
ABP Yearly EPS VS EstimatesABP Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABP. In the last year negative earnings were reported.
Also next year ABP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABP Price Earnings VS Forward Price EarningsABP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABP Per share dataABP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A cheap valuation may be justified as ABP's earnings are expected to decrease with -23.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.8%
EPS Next 3Y-23.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABPRO HOLDINGS INC

NASDAQ:ABP (7/25/2025, 8:00:00 PM)

After market: 0.318 +0 (+0.82%)

0.3154

+0.05 (+18.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners7.1%
Inst Owner Change0%
Ins Owners3.06%
Ins Owner Change0.22%
Market Cap19.17M
Analysts80
Price Target2.04 (546.8%)
Short Float %N/A
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 104.77
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS-0.25
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -396%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-240.71%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -46.17
F-Score4
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2966.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-776.85%
EPS Next Y0%
EPS Next 2Y-11.8%
EPS Next 3Y-23.31%
EPS Next 5YN/A
Revenue 1Y (TTM)289.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-117.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.99%
OCF growth 3YN/A
OCF growth 5YN/A